{"id":47561,"date":"2022-08-23T12:01:36","date_gmt":"2022-08-23T10:01:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-alzheimers-disease-therapeutics-and-diagnostics-market-2022-2028-prevalence-of-alzheimers-disease-a-rise-in-the-elderly-population-driving-sector-growth-researchandmarkets-com\/"},"modified":"2022-08-23T12:01:36","modified_gmt":"2022-08-23T10:01:36","slug":"global-alzheimers-disease-therapeutics-and-diagnostics-market-2022-2028-prevalence-of-alzheimers-disease-a-rise-in-the-elderly-population-driving-sector-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-alzheimers-disease-therapeutics-and-diagnostics-market-2022-2028-prevalence-of-alzheimers-disease-a-rise-in-the-elderly-population-driving-sector-growth-researchandmarkets-com\/","title":{"rendered":"Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2022-2028: Prevalence of Alzheimer’s Disease & a Rise in the Elderly Population Driving Sector Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2022-2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nMARKET OUTLOOK<\/strong>\n<\/p>\n

\nThe publisher estimates the global Alzheimer’s disease therapeutics and diagnostics market to grow with a CAGR of 6.98% in the years 2022-2028.\n<\/p>\n

\nThe high prevalence of Alzheimer’s disease (AD) and the growing elderly populace are key factors driving the growth of this market. The elderly population is at an increased risk of developing this disease, which is expected to aid the demand for therapeutics and diagnostics. However, stringent regulations by the government, as well as the failure of the late-stage drugs in clinical trials, are hampering the growth of this industry. On the bright side, the emergence of novel diagnostic technologies for AD treatment is creating new avenues for the market’s development.\n<\/p>\n

\nREGIONAL OUTLOOK<\/strong>\n<\/p>\n

\nThe global market for Alzheimer’s therapeutics and diagnostics spans Europe, the Asia-Pacific, Latin America, the Middle East and Africa, and North America.\n<\/p>\n

\nNorth America held the largest share in the global market in 2021, and is anticipated to maintain its lead by the end of the forecast period. Developed nations, such as the US and Canada, are considered in the market in this region. Factors such as the rising geriatric population and the growing burden of Alzheimer’s disease contribute to the growth of the market in North America. Statistics indicate that 1 in every 9 people in the US, aged 65 years or older, is affected by AD. This has enhanced the demand for developing novel therapeutics and diagnostics for Alzheimer’s.\n<\/p>\n

\nMarket Dynamics<\/strong>\n<\/p>\n

\nMarket Drivers\n<\/p>\n